We came across a bullish thesis on Sana Biotechnology, Inc. (SANA) on wallstreetbets Subreddit Page by Intrepid_Web5454. In ...

As researchers push for a type 1 diabetes cure, Sana Biotechnology has provided a nudge forward with new, if limited, ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 45.04% ...

On Tuesday, Sana Biotechnology Inc (SANA) stock saw a decline, ending the day at $2.92 which represents a decrease of $-0.24 or -7.59% from the prior close of $3.16. The stock opened at $3.17 and ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with type 1 diabetes, sending the company’s share price up by about 200%.

Samantha Semenkow, an analyst from Citi, maintained the Buy rating on Sana Biotechnology (SANA – Research Report). The associated price target remains the same with $15.00. Discover ...

Sana is a gene and cell therapy clinical-stage biotech firm and a penny stock that has fallen by 48.5% in the year leading to January 17, 2025. What may set this company apart from a host of similar ...

Adams joined the Seattle-based biotech giant more than three… Read More Seattle-based cell and gene therapy company Sana Biotechnology will reduce its workforce by 15%, according to a statement ...

Analyst Vikram Purohit from Morgan Stanley maintained a Buy rating on Sana Biotechnology (SANA – Research Report) and keeping the price target ...

The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...